Conferences - Results from #360

Viewing 361-380 of 11775 articles

ASCO 2024: Nivolumab and Ipilimumab for Metastatic Prostate Cancer with an Immunogenic Signature: The NEPTUNES Multi-Centre Two-Cohort, Biomarker-Selected Phase 2 Trial

ASCO 2024: Oncogenic Alteration Rates, Race, and Prostate Cancer Specific Mortality in Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor next Generation Sequencing

ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial

ASCO 2024: HERCULES (LACOG 0218): A Phase II Trial of Pembrolizumab plus Platinum-Based Chemotherapy as First-Line Systemic Therapy in Advanced Penile Cancer

ASCO 2024: A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Abiraterone + Docetaxel in Patients with Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2024: Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial

ASCO 2024: Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

ASCO 2024: Partitioned Overall Survival: Comprehensive Analysis of Survival States over 4 Years in CheckMate 9ER Comparing First-Line Nivolumab plus Cabozantinib Versus Sunitinib in Advanced Renal Cell Carcinoma

ASCO 2024: Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial

ASCO 2024: Circulating Kidney Injury Molecule-1 Biomarker Analysis in IMmotion010: A Randomized Phase 3 Study of Adjuvant Atezolizumab vs Placebo in Patients with Renal Cell Carcinoma at Increased Risk of Recurrence After Resection

ASCO 2024: In It for the Long Run: Updated Outcomes From Phase III Trials

ASCO 2024: Impact of Exposure on Outcomes with Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer

ASCO 2024: S1600: Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial

ASCO 2024: PROs from a Randomized, Phase 3 Trial of Enfortumab Vedotin plus Pembrolizumab Versus Platinum-Based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

ASCO 2024: PLATIPARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients with mCRPC with Homologous Recombination DNA Repair Deficiency

ASCO 2024: CLARIFY: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy (A Phase 3 Diagnostic Study)

ASCO 2024: ALADDIN: Evaluation of Darolutamide Addition to ADT and Radiation Therapy in Newly Diagnosed Prostate Cancer with Pelvic Lymph Nodes Metastases

ASCO 2024: FLEX-MRT: A Randomized Phase 2 Trial in Progress of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy in mCRPC

ASCO 2024: ARASTEP: Darolutamide plus ADT in Patients with High-Risk Biochemical Recurrence of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

ASCO 2024: Comparison of Outcomes with Docetaxel or ARPI Combination Therapy for mHSPC by Volume of Disease

14
15
16
17
18
19
20
21
22
23